The E2F transcription factor is a key cell cycle regulator. However, the inactivation of the entire E2F family in Drosophila is permissive throughout most of animal development until pupation when ...
Anaheim, CA - A gene therapy called E2F Decoy (Corgentech Inc, Palo Alto, CA), designed to prevent graft failure, has proved safe and feasible for use in human vein grafts in CABG, and hints at being ...
The E2F-1 promoter has been used to confer tumor-selective E1A expression in oncolytic adenoviruses. Tumor specificity is mainly conferred by a unique structure of E2F-responsive sites organized in ...
Mice develop pancreatic diabetes when they lack certain genes in the E2F group, and to understand how this happens, scientists have focused on the molecular mechanism behind it. Mice develop ...
Real-world multicentre analysis of patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (A+B): Efficacy, esophagogastroduodenoscopy (EGD) uptake and bleeding ...
It's the kind of mirror image Corgentech Inc. didn't want: Only a few months after reporting a Phase III failure for edifoligide (E2F Decoy), its partnered product with Bristol-Myers Squibb Co., the ...
Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma Overexpression of TP73 variants in tumor tissues indicates that they ...
Circle Pharma Announces Publication in Journal of Medicinal Chemistry Highlighting Optimization of First-in-Class Oral Cyclin A/B RxL Inhibitors Research describes progress of discovery-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results